Figures
Abstract
The goal of our study was to investigate the contribution of ABCB1 expression to the risk of clopidogrel resistance (CR). Platelets functions were measured using the Verify-Now P2Y12 assay. Applying Polymerase Chain Reaction–Restriction Fragment Length Polymorphism (PCR-RFLP), the single-nucleotide polymorphisms (SNPs) was tested. Using bisulphite pyrosequencing assay, we investigated the association of the ABCB1 DNA methylation levels and CR. It was shown that female, hypertension, and lower albumin levels increased the risk of CR (P<0.05). If patients did not have hypoproteinaemia or had hypertension, the SNP in rs1045642 was associated with CR (CC vs. TT: albumin ≥35, P = 0.042; hypertension, P = 0.045; C vs. T: albumin ≥35, P = 0.033; hypertension, P = 0.040). Additionally, the platelet inhibition of the CT+TT genotype in rs1128503 was larger than that of the CC genotype (P = 0.021). Multivariate logistic regression analysis showed that male, higher albumin and hsCRP decreased the risk of CR, and the stent size maybe positively correlated with CR. The SNP in rs1045642 was related to all-cause mortality (P = 0.024). We did not find any relationship between the methylation levels of the ABCB1 promoter and CR. In conclusions, our study indicated that ABCB1 polymorphisms might be useful in further evaluating the pathogenesis of CR.
Citation: Su J, Yu Q, Zhu H, Li X, Cui H, Du W, et al. (2017) The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. PLoS ONE 12(3): e0174511. https://doi.org/10.1371/journal.pone.0174511
Editor: Andreas Zirlik, Universitatsklinikum Freiburg, GERMANY
Received: June 22, 2016; Accepted: February 28, 2017; Published: March 30, 2017
Copyright: © 2017 Su et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper.
Funding: The authors received the funding of the Plan of Science and Technology on Medicine and Health in Zhejiang Province (2017KY574) for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
At sites of vascular injury due to atherosclerotic plaque rupture or erosion, platelets mediate not only haemostasis but also pathologic thrombosis[1]. Thrombus generation (due to platelet activation and aggregation) is the main process involved in atherosclerotic vascular disease, particularly coronary artery disease (CAD)[2]. Therefore, antiplatelet therapy has been the cornerstone therapy in patients with coronary artery disease, especially in those undergoing percutaneous coronary intervention (PCI)[3].
Through inhibiting the purinergic ADP receptor P2Y12, clopidogrel reduces adenosine diphosphate-induced platelet aggregation and decreases the risk of cardiovascular events in CAD patients[4]. However, a large number of patients continue to suffer recurrent ischaemic events[5], and this clinical phenomenon has been correlated with lesser degrees of platelet inhibition[6]. This failure of the antiplatelet drug to inhibit its target of action is called clopidogrel non-responsiveness or clopidogrel resistance[7]. Recently, both prasugrel and ticagrelor, which are novel and stronger antiplatelet agents, were shown to exert more consistent, rapid and effective P2Y12 receptor inhibition in patients with acute coronary syndrome (ACS)[8]. Nevertheless, high incidence of major bleeding in some patients receiving prasugrel was noted[9], and ticagrelor was associated with an 11% increase in combined major and minor PLATO bleeding rates after careful analysis of bleeding events[10]. And cases of inadequate platelet inhibition of prasugrel had been occasionally reported however the incidence of this is less than clopidogrel resistance and this is in keeping with prasugrel being a prodrug[11]. Therefore, clopidogrel remains to be one of the most extensively prescribed antiplatelet drugs in CAD patients, and research focused on the individual susceptibility to clopidogrel is of vital significance.
Several clinical and demographic factors may influence the antiplatelet efficacy of clopidogrel, such as drug-drug interactions (such as Proton pump inhibitors[12]), renal dysfunction, diabetes mellitus (DM), diet, smoking, age, reduced left ventricular function, inflammation and the presence of an ACS[13]. However, genetic factors, specifically the expression of the ABCB1 gene, may significantly influence clopidogrel’s response[14].
Clopidogrel is an oral, second-generation thienopyridine irreversible inhibitor of the P2Y12 receptor. It undergoes rapid absorption by the duodenum and is metabolized by hepatic cytochrome P450 enzymes. About 15% of clopidogrel’s prodrug is converted into a biologically active thiol metabolite, which, in circulation, irreversibly combines to and inactivates the P2Y12 receptor on the surfaces of platelets, resulting in the inhibition of ADP-induced platelet activation and aggregation[15]. In the above transformation, specific genetic variants are responsible for clopidogrel’s transport (ATP-binding cassette subfamily B member 1 [ABCB1]), metabolism (CYP enzymes, paraoxonase-1) and action (P2Y12)[16].
The ABCB1 gene, which is also called MDR1 or TAP1, encodes the intestinal efflux transporter pump P-glycoprotein and modulates the absorption of clopidogrel[17]. The effect of different levels of ABCB1 expression is unclear. Simon et al.[18] first analysed the influence of the ABCB1 C3435T (rs1045642) polymorphism on clinical outcomes in persons treating with clopidogrel and found that homozygous patients had a higher risk of cardiovascular events. One recent study was found that exposition to clopidogrel, measured by AUC0-t of the drug, was significantly lower in TT homozygotes comparing to CC and CT genotypes (ABCB1 3435C>T), which showed that the presence of 3435C>T allele had an impact on clopidogrel pharmacokinetics[19]. However, these findings could not be confirmed in several subsequent studies. Additionally, the effect of the rs1128503 polymorphism and the DNA methylation of selected CpG islands in the ABCB1 gene on clopidogrel’s response are poorly understood. Thus, in the present study, we attempted to assess whether the rs1045642 and rs1128503 polymorphisms and DNA methylation in the ABCB1 promoter are involved in clopidogrel resistance in Chinese CAD patients treated with clopidogrel.
Methods
Study population
From 2010 to 2015, a total of 180 patients with acute coronary syndromes (ACS) were enrolled in present study in the Ningbo No. 1 Hospital. All of them were Han Chinese from Ningbo city in Eastern China. The inclusion criteria were as follows: (1) According to the most recent guidelines (ACC/AHA guidelines), all individuals were undergoing PCI through the radial route via a drug-eluting stent. The patients we tested the platelet function were mostly existed multi-vessel or left main vessel disease of the coronary artery. (2) The patients received clopidogrel (300 mg) and aspirin (300 mg) before PCI and were administered clopidogrel 75 mg and aspirin 100 mg daily. (3) The patients’ age was required to be ≥18 years. The exclusion criteria were as follows: (1) the therapy of concomitant glycoprotein IIb/IIIa inhibitor or warfarin, (2) hepatic or renal insufficiency, (3) history of active bleeding diathesis, (4) hepatic and renal insufficiency, and (5) total platelet count < 150 000 μl-1 or > 500 000 μl-1. All patients provided written informed consent before participation in the research. The study protocol was reviewed and approved by the Ethics Committee of Ningbo No1. Hospital and conformed to the guide lines of the Declaration of Helsinki.
Collection of blood samples and clinical data
Blood samples were obtained overnight via venipuncture in the antecubital area. Serologic markers, such as the concentrations of TC, TG, LDL, GLU, HbA1c, BUN, and CREA, were detected. All the measures applied the standard procedures, and data were collected.
Platelet function measurements
With the administration of clopidogrel for 3 to 5 days, the platelet reactivity may have been stable or not significantly changed in AMI patients undergoing PCI[20]. We detected the platelet reactivity one month after PCI. By the double-syringe technique, blood samples were gathered and the first 5 ml was discarded to avert unprompted platelet activation. The platelet function measurements were analysed by the VerifyNow P2Y12 assay (Accumetrics Inc., San Diego, California), which was developed to assess the response to P2Y12 antagonists[21]. The VerifyNow P2Y12 assay reported P2Y12 reaction units (PRU), and a PRU more than 240 reaction units suggested the existence of clopidogrel resistance[22].
Genomic DNA extraction, genotyping, and methylation assay
Human genomic DNA was extracted from 3 ml peripheral blood by QIAamp DNA BloodMini Kit (Qiagen). Samples were stored at -100°C until use. PCR primers were planned through PyroMark Assay Design software. The sequences of primers used in the SNP genotyping and DNA Methylation Assay are described in Table 1.
Polymerase chain reaction (PCR) amplification (BIO-RAD C1000touch Thermal Cycler PCR) was performed as follows: 50 μl reaction volume containing 1 μl template DNA, 1.5 μl 10 mM dNTP, 5 μl Taq Buffer, 1.0 μl25 mM MgCl2, 1.5 μl upstream and downstream primers, 1 μl platinum Taq polymerase 1 U and 37.5 μl water. PCR cycling conditions consisted of 2 cycles of 94°C denaturation for 2 min, 30 cycles of 94°C denaturation for 30 sec, 55°C annealing for 45 sec, and 68°C extension for 3 min, and one cycle of 68°C repair extension for 10 min. PCR products were purified (SK1141; kit Sangon Biotech), measured (3500XL sequence analyser; ABI), and sequenced.
The bisulphite pyrosequencing technology was applied to evaluate the quantitative DNA methylation of 2 CpG dinucleotides on the fragment of ABCB1 gene promoter[23]. This process was also combined with sodium bisulphite DNA conversion chemistry (EpiTech Bisulphite Kits; Qiagen), polymerase chain reaction amplification (Pyromark PCR Kit; Qiagen) and sequencing (Pyromark Gold Q24 Reagents; Qiagen) of the target fragment[24].
Statistical analysis
Quantitative data are described as the mean ± standard deviation for categorical variables or the median with interquartile range (IQR) for continuous variables. We carried out a suite of statistical analyses to investigate the association among genetic variables, various confounding factors and clopidogrel resistance. Categorical variables were analysed with either Pearson’s chi-square test or Fisher’s exact test when appropriate. Continuous variance with normality and homogeneity were applied to compare the mean values from t-tests. Non-parametric continuous variance was performed using the Wilcoxon rank-sum test. Logistic regression was used to test the interaction of ABCB1 SNP and confounding variables. All the statistical analyses were conducted by PASW Statistics 18.0 software (SPSS, Inc., Somers, NY, USA). A value of P less than 0.05 was considered to indicate a statistically significant difference.
Results
Study population
From May 2010 to October 2015, 180 CAD patients who met all requirements were recruited for the present study. UsingVerifyNowP2Y12 assay, 81 patients whose PRU was greater than 240 were defined as having a poor clopidogrel response or clopidogrel resistance. The demographic and clinical characteristics of the cases and controls are summarized in Table 2. The clinical information was well matched except for albumin and the ratios of gender and hypertension. Patients with poor clopidogrel response were more likely to be female (cases versus controls: 32.1% versus 15.15%, P = 0.007) and have hypertension (cases versus controls: 75.31% versus 58.59%, P = 0.018) and lower albumin levels (cases versus controls:38.11 ± 4.38 versus 39.83 ± 5.64, P = 0.026). These data indicated that female sex, hypertension and lower albumin levels might increase the risk of clopidogrel resistance.
Clopidogrel resistance and thers1045642 and rs1128503 polymorphisms
It was well known that the variance of rs1045642 and rs1128503is common in Chinese populations. We searched the genetic information of CHB on the HAP-MAP and found that the frequency of the C allele in ABCB1 3435C>T (rs1045642) and the C allele in ABCB1 1236C>T (rs1128503) in Chinese populations are 0.613 and 0.293. We calculated the frequency of these two SNP in our study and ensured that each of the target polymorphisms was in Hardy–Weinberg equilibrium (Table 3).
Through PCR-HPCE, we explored the association of clopidogrel resistance and the rs1045642 and rs1128503 polymorphisms. As shown in Table 4, our results showed that the variation of rs1045642 and rs1128503 was not significantly associated with clopidogrel resistance (Prs1045642 = 0.288; Prs1128503 = 0.644).
Additionally, we determined the relationship by the comparison of the different SNP modes (homozygotes and dominant, recessive and heterozygous models), and the results were insignificant (Table 5).
Subgroup analysis
Due to the differences in the baseline characteristics between the CR and NCR patients, we carried out subgroup analysis according to the ratios of males, hypertension and albumin. Overall, there was no significant difference for any subgroup (Table 6).
However, we tested the relationship between platelet activity and the four SNP modes, producing new significance values. For rs1045642, in patients with hypertension or a value of albumin greater than 35, patients with the CC genotype had a higher risk of CR than those with the TT genotype (albumin≥35, P = 0.042; hypertension P = 0.045). At the same time, patients with the C allele were more likely to have an increased risk of CR than those with the T allele (albumin≥35 P = 0.033; hypertension P = 0.040)(Table 7).
Different SNP modes and the index of platelet function
The Verify-Now assay measures the agonist-induced activation of platelets and their binding to fibrinogen-coated polystyrene beads. The assay uses ADP as an agonist and PGE1 as an antagonist, and the results are reported as P2Y12 reaction units (PRU)[25].With this test, we obtained the value of PRU, the baseline of platelet activity, and the inhibition value. The inhibition value is equivalent to (baseline-PRU)/baseline. We compared the relationship between the SNP and PRU, as well as inhibition, and did not find any significant results (Table 8).
Because we tested the relationship between platelet activity and the four SNP modes, it became clear that a significant association existed. For ABCB1236C>T (rs1128503), compared with the genotype of CC, the inhibition of platelets in patients with CT+TT was much higher (P = 0.021), which contributed to clopidogrel resistance (Table 9 and Fig 1).
(1) PRU(CC vs. CT+TT: 225.21±77.50 vs. 226.40±65.77; P = 0.689). (2) Inhibition (CC vs. CT+TT(%): 0.23±0.19 vs. 0.34±0.17; P = 0.021).
The relationship between clopidogrel resistance and methylation levels
In the present study, we chose 106 patients at random and found 49 with a poor response to clopidogrel after the platelet function test. We selected a fragment (GRCh37.p13: 87344039–87341039) that contained 2 CpG dinucleotides. Through the bisulphite pyrosequencing assay, we investigated the association of clopidogrel resistance and ABCB1 gene promoter DNA methylation levels in these 106 CAD patients. Additionally, as shown in Fig 2 and Table 10, the methylation levels of CpG1 in ABCB1 in selected fragments were not significantly related to clopidogrel resistance (cases versus controls(%): 90.84±3.42 versus 91.18±2.27, P = 0.545) along with ABCB1 CpG2 (cases versus controls (%): 92.65±4.52 versus93.53±4.12, P = 0.408). Although we tried to perform a breakdown analysis according to clinical characteristics, we could not find any relationship between the methylation levels of the ABCB1 gene promoter (including CpG1 and CpG2) and poor response to clopidogrel.
ABCB1 CpG1 (cases vs. controls (%):90.84±3.42 vs. 91.18±2.27, P = 0.545) and ABCB1 CpG2 (cases vs.controls (%):92.65±4.52 vs. 93.53±4.12, P = 0.408).
Multivariate logistic regression
Respecting the influence of confounding factors, we implemented logistic regression analysis with clinical and genetic variables. The results showed that the TT genotype (rs1045642) was a protective factor of clopidogrel resistance in the homozygotes mode (TT vs. CC:OR = 0.073, P = 0.024). Additionally, the indexes (such as male sex, hyperlipidaemia, HDL, hsCRP, and EF) were inversely correlated with CR, whereas the values of LDL, UA, and the number of stents were associated with CR (Table 11).
Clinical events and genotype in rs1045642 and rs1128503
For these 180 patients, we performed clinical follow-ups for one year. In this year, there were 30 non-fatal myocardial infarctions, 7 non-fatal strokes, 7 cardiovascular deaths, 2 deaths from other causes (1 acute pancreatitis and 1 renal insufficiency), 29 cases of stent thrombosis, and 10 cases of minor or major bleeding. We explored the association between the genotype of rs1045642 and rs1128503 and the risk of cardiovascular events after receiving clopidogrel for one year. The results indicated that the SNP of rs1045642 was related to all-cause mortality (P = 0.024) (Table 12). However, we could not identify the susceptible genotype due to the limited sample size.
Discussion
The ABCB1gene, located at 7, p21–21.1,[26], encodes the intestinal efflux transporter P-glycoprotein. The P-glycoprotein plays an important role in the bioavailability of multiple endogenous and xenobiotic compounds (such as clopidogrel) from the intestinal lumen via duodenal enterocytes[17]. Recent research revealed that C3435T SNP (rs1045642) was related to an increase in ulcerative colitis, whereas it was associated with tacrolimus pharmacokinetics and the response to platinum-based chemotherapy in lung cancer[27]. Simon et al.[18] first analysed the influence of the ABCB1 C3435T polymorphism on clinical outcomes in persons on clopidogrel and found that homozygous patients had an increasing risk of cardiovascular events. However, many other studies showed controversial findings in several subsequent periods. It was reported that the genotype of ABCB1 C1236T (rs1128503) might influence the incidence of breast cancer[28], osteonecrosis[29], and multiple myeloma[30], and the methylation level of the partial ABCB1 gene promoter is closely linked to the efficacy of interventional embolism chemotherapy for cervical cancer[31]. However, there is little information regarding the influence of thers1128503polymorphism and the DNA methylation of selected CpG islands in the ABCB1 gene on clopidogrel’s response.
In the present study, with the application of the Verify-Now P2Y12 assay for platelet function tests in clinical practice and the use of polymerase chain reaction-high performance capillary electrophoresis (PCR-HPCE) for sequencing, we found that if patients had no hypoproteinaemia or had hypertension, the SNP in rs1045642 was associated with CR (CC vs. TT: albumin ≥35, P = 0.042; hypertension, P = 0.045; C vs. T: albumin ≥35, P = 0.033; hypertension, P = 0.040). Additionally, the SNP in rs1045642 was related to the all-cause mortality after one-year follow-up. These data were not consistent with previous research[32] and our most recent meta-analysis[33]. These inconsistent results might be due to the variance of gene frequency in different populations in different areas. Searching the HAPMAP, the information showed that the frequency of the C allele in rs1045642 in Chinese patients was slightly higher than that of Caucasians. A recent study from east asians was indicated that CYP2C19 PM along with ABCB1 3435 TT status was a strong independent predictor of the primary end point (deaths, non-fatal MIs and strokes)[34]. Hence, the variance of the cardinal number in patients with three genotypes resulted in the inconsistent findings compared to the former study. Moreover, to some extent, the limited sample size might have led to statistical bias.
Our results showed that the platelet inhibition of the CT+TT genotype in rs1128503 was larger than that of the CC genotype (P = 0.021).This study was the first to include rs1128503 in the association with the degree of platelet inhibition evaluated by Verify-Now P2Y12 assay. The most recent findings may elicit a novel target and help us to screen the susceptible locus with a new perspective. There are more than 50 single-nucleotide polymorphisms (SNP) in ABCB1. Among them, rs1045642 and rs1128503 are the most common in Chinese patients. Here, we selected these two loci, but we were unable to perform an interaction analysis due to the limited sample size. One study showed that coexisting polymorphisms of the P2Y12 and CYP2C19 genes might be related to persistent platelet activation while on clopidogrel[35]. Another recent study reported that the coexistence of QT mutations/polymorphisms in patients with tetralogy of Fallot (TOF) might aggravate abnormal repolarization after cardiac repair and increase the risks of life-threatening events[36]. Therefore, gene-gene interactions, such as those of CYP3A4 or CYP2C19 or PON1 with ABCB1, need to be studied. Additional studies with larger sample sizes might give us a chance to improve and perfect our limitations.
Applying bisulphite pyrosequencing, we evaluated the DNA methylation levels of two CpG dinucleotides on the ABCB1 promoter region. However, no significance was detected between antiplatelet response and methylation status. Various trials have focused on epigenetics, such as miRNA, siRNA, and DNA methylation. DNA methylation is a reliable epigenetic marker and specifically occurs in the context of cytosine-phosphate guanine (CpG) dinucleotide[37]. The hypermethylation of vertebrate CpG islands (CGIs) is relative to the transcriptional silencing of gene expression and thus controls the protein level[38]. It was found that aberrant methylation plays a vital role in the occurrence and development of diseases, including adrenocortical cancer[39], age-associated cancer[40], coronary artery disease[41], and psychotic disorders[42]. Two years ago, we investigated the contribution of P2Y12 promoter DNA methylation to the risk of clopidogrel resistance (CR) and discovered that the lower methylation of two CpGs indicated that the CR in alcohol abuse and CpG1methylation was inversely correlated to CR in smokers and in the albumin subgroup[24]. To the best of our knowledge, this was the first study on the topic of DNA methylation and CR. The ABCB1 results were not significant, which was inconsistent with another study that showed that hypomethylation of the ABCB1 promoter is related to a poor response to clopidogrel in ischaemic stroke patients[43]. Although there were differences in the study subjects (coronary artery disease and stroke), the population, drug, and the dose were all uniform. These inconsistent findings might be due to the varying regions of CpGIs each study selected. Bisulphite pyrosequencing chose a random region of CpGIs and could not cover the entire area. Thus, sequencing in various regions resulted in inconsistent conclusions. We aim to perform additional studies and a more advanced empirical approach to validate our findings in the future.
The genotype accounts for approximately 2% to 12% of inter-individual variability of the response to clopidogrel[44], and various extrinsic factors (environment, comorbidities, and drug interactions) may also contribute to clopidogrel resistance[45]. We performed logistic regression analysis with confounding variables and showed that male sex and higher levels of albumin and hsCRP decreased the risk of CR, and the number of stents may be positively correlated with CR. These were similar with the study by Gremmel etal, which reported that lower platelet reactivity assessed by the VerifyNow P2Y12 assay were associated with increased levels of hsCRP[46], and the study by Tan etal, which indicated that the number of stents was associated with higher risks of thromboembolic events[47]. Additionally, a recent study showed that chronic kidney disease (CKD) seemed to be associated with poor response to clopidogrel and the high incidence of stent thrombosis in diabetic patients after PCI[48], which might be due to the increased platelet turnover and the up-regulation of the P2Y12 pathway[49]. Hochholzer et al revealed that theCYP2C19*2 polymorphism along with clinical factors (age, diabetes mellitus, body mass index, platelets, verapamil/diltiazem) could replace the phenotyping of platelet function[50]. All these factors demonstrated that the phenomenon of CR was affected by multiple extrinsic and intrinsic factors.
Dual-antiplatelet functions and statins are essential to the proper treatment of CAD, especially after PCI. In follow-up studies, the efficiency of antiplatelet and the influence of statins on atherosclerosis and ischaemic endpoints should be evaluated. If the LDL-C level was greater than 1.3 mmol per litre, the absolute CV risk would decrease in combination with a decrease in LDL-C [51]. A study on IMPROVE-IT reported a clear benefit in the reduction in major cardiovascular (CV) events with simvastatin and ezetimibe therapy[52]. The expression of the gene could also influence the lipid-lowering efficacy, and our most recent meta-analysis indicated that the ABCB1 C3435T polymorphism might be a pharmacogenomic biomarker for predicting clinical outcomes in patients with statins[53]. Therefore, we should consider the effect of statins in the present study, although we discovered that the ABCB1 C3435T polymorphism was related to the all-cause mortality under treatment with clopidogrel in CAD patients. However, the various types of statins and small sample size in our study limited the exploration of the underlying relationship.
Numerous tests are available for measuring platelet function and predicting clopidogrel response, such as the flow cytometric vasodilator-stimulated phosphoprotein phosphorylation (VASP) analysis, the Verify-Now P2Y12 assay, PFA-100, whole blood thromboelastography and impedance aggregometry (multiplate analyzer)[45]. However, various studies in different areas applied distinct methods and cut-off values. Therefore, a common operation standard and evaluation system were urgently required. We produced a systemic and predictive clinical score, which consisted of extrinsic and intrinsic elements, to screen the CR patients. Recently, Fontana[54] and Geisler[55] provided two novel scoring standards, but both of them require further validation. Moreover, if clopidogrel resistance is present, action would be taken to overcome the high platelet reactivity: increasing the loading dose or/and maintenance dose or adding another antiplatelet drug (cilostazol), or changing clopidogrel to a newer thienopyridine, such as prasugrel or ticagrelor. Despite the decline in ischaemic cardiovascular events, these agents produce a higher risk of bleeding [56].
This study presents inherent limitations. First, the sample size was small. Further study with larger sample sizes could be designed for further evaluation. Second, we chose only one fragment of the CGI from the promoter of the ABCB1 gene, and there might be other region correlated to CR. Thus, the conclusions should be interpreted with caution. Third, in gene-gene or gene-drug or gene-environment interactions, unknown confounding factors might exist and affect the expression of the ABCB1 gene, which led to biased results. The exact interactions remain to be investigated in future studies.
5.Conclusions
In summary, our study found that the SNP in rs1045642 was associated with CR in patients with hypertension or albumin ≥35 and was related to all-cause mortality. The platelet inhibition of the CT+TT genotype in rs1128503 was larger than that of the CC genotype. Additionally, the methylation of the ABCB1 gene promoter did not affect clopidogrel’s response. Finally, multivariate logistic regression showed that male sex and higher levels of albumin and hsCRP were associated with a decreased risk of CR, and the number of stents may be positively correlated with CR. All these data might provide new insight to elaborate the pathogenesis of CR. However, we aim to perform larger studies with more effective planning and a more advanced empirical approach to validate our findings in further research.
Acknowledgments
We thank Yaqing Wang and Shujun Yang for excellent technical assistance. The authors also thank Dr Jin Xu for editing the manuscript.
Author Contributions
- Conceptualization: JS XC JY.
- Data curation: WD YZ HX JZ YZ YX TL.
- Formal analysis: JS QY HZ LJ.
- Funding acquisition: XC JY.
- Investigation: JS XL HC MT.
- Methodology: JS XL HC MT QY JY.
- Project administration: JS XC JY.
- Resources: XL HC MT.
- Software: JS QY HZ.
- Supervision: XC JY.
- Validation: HZ JY.
- Visualization: JS QY HZ.
- Writing – original draft: JS.
- Writing – review & editing: XC JY.
References
- 1. Franchi F, Angiolillo DJ (2015) Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 12: 30–47. pmid:25286881
- 2. Jennings LK (2009) Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 102: 248–257. pmid:19652875
- 3. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. (2010) Guidelines on myocardial revascularization. Eur Heart J 31: 2501–2555. pmid:20802248
- 4. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr., et al. (2013) 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127: e663–828. pmid:23630129
- 5. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, et al. (2016) Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 37: 390–399. pmid:26324537
- 6. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, et al. (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48: 1742–1750. pmid:17084243
- 7. Nguyen TA, Diodati JG, Pharand C (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45: 1157–1164. pmid:15837243
- 8. Kubica A, Kasprzak M, Siller-Matula J, Kozinski M, Pio Navarese E, Obonska K, et al. (2014) Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol 742: 47–54. pmid:25199965
- 9. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001–2015. pmid:17982182
- 10. Wiviott SD, Steg PG (2015) Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet 386: 292–302. pmid:25777663
- 11. Alexopoulos D (2012) Prasugrel resistance: fact or fiction. Platelets 23: 83–90. pmid:21787175
- 12. Fernando H, Dart AM, Peter K, Shaw JA (2011) Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost 105: 933–944. pmid:21544314
- 13. Cayla G, Hulot JS, O'Connor SA, Pathak A, Scott SA, Gruel Y, et al. (2011) Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 306: 1765–1774. pmid:22028352
- 14. Campo G, Fileti L, Valgimigli M, Tebaldi M, Cangiano E, Cavazza C, et al. (2010) Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis 30: 319–331. pmid:20157839
- 15. Sangkuhl K, Klein TE, Altman RB (2010) Clopidogrel pathway. Pharmacogenet Genomics 20: 463–465. pmid:20440227
- 16. Beitelshees AL, Voora D, Lewis JP (2015) Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med 8: 43–61. pmid:25897256
- 17. Gros P, Ben Neriah YB, Croop JM, Housman DE (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728–731. pmid:3022150
- 18. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363–375. pmid:19106083
- 19. Karazniewicz-Lada M, Danielak D, Rubis B, Burchardt P, Komosa A, Lesiak M, et al. (2015) Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. J Clin Pharm Ther 40: 226–231. pmid:25430046
- 20. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109: 3171–3175. pmid:15184279
- 21. Kim IS, Jeong YH, Kang MK, Koh JS, Park Y, Hwang SJ, et al. (2010) Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. J Thromb Thrombolysis 30: 486–495. pmid:20449634
- 22. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. (2009) Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119: 237–242. pmid:19118249
- 23. Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D, Schramm J, et al. (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9: 368–381. pmid:17591937
- 24. Su J, Li X, Yu Q, Liu Y, Wang Y, Song H, et al. (2014) Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. Biomed Res Int 2014: 450814. pmid:24745016
- 25. Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, et al. (2008) The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 99: 409–415. pmid:18278193
- 26. Fojo A, Lebo R, Shimizu N, Chin JE, Roninson IB, Merlino GT, et al. (1986) Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Mol Genet 12: 415–420. pmid:3016920
- 27. Brambila-Tapia AJ (2013) MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev Invest Clin 65: 445–454. pmid:24687344
- 28. Abuhaliema AM, Yousef AM, El-Madany NN, Bulatova NR, Awwad NM, Yousef MA, et al. (2016) Influence of Genotype and Haplotype of MDR1 (C3435T, G2677A/T, C1236T) on the Incidence of Breast Cancer—a Case-Control Study in Jordan. Asian Pac J Cancer Prev 17: 261–266. pmid:26838221
- 29. Zhang Z, Li Y, Liu H, Shi J, Li X, Jiang W (2015) ABCB1 polymorphisms associated with osteonecrosis of the femeral head. Int J Clin Exp Pathol 8: 15240–15244. pmid:26823873
- 30. Yin G, Xiao Z, Ni Y, Qu X, Wu H, Lu H, et al. (2016) Association of MDR1 single-nucleotide polymorphisms and haplotype variants with multiple myeloma in Chinese Jiangsu Han population. Tumour Biol.
- 31. Huang Z, Zhang S, Shen Y, Liu W, Long J, Zhou S (2016) Influence of MDR1 methylation on the curative effect of interventional embolism chemotherapy for cervical cancer. Ther Clin Risk Manag 12: 217–223. pmid:26929635
- 32. Spiewak M, Malek LA, Kostrzewa G, Kisiel B, Serafin A, Filipiak KJ, et al. (2009) Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. Kardiol Pol 67: 827–834. pmid:19784880
- 33. Su J, Xu J, Li X, Zhang H, Hu J, Fang R, et al. (2012) ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One 7: e46366. pmid:23056288
- 34. Park MW, Her SH, Kim CJ, SunCho J, Park GM, Kim TS, et al. (2016) Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians. Genet Med 18: 833–841. pmid:26699760
- 35. Malek LA, Kisiel B, Spiewak M, Grabowski M, Filipiak KJ, Kostrzewa G, et al. (2008) Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 72: 1165–1169. pmid:18577829
- 36. Chiu SN, Wu MH, Su MJ, Wang JK, Lin MT, Chang CC, et al. (2012) Coexisting mutations/polymorphisms of the long QT syndrome genes in patients with repaired Tetralogy of Fallot are associated with the risks of life-threatening events. Hum Genet 131: 1295–1304. pmid:22407026
- 37. Razin A, Webb C, Szyf M, Yisraeli J, Rosenthal A, Naveh-Many T, et al. (1984) Variations in DNA methylation during mouse cell differentiation in vivo and in vitro. Proc Natl Acad Sci U S A 81: 2275–2279. pmid:6585800
- 38. Morita S, Takahashi RU, Yamashita R, Toyoda A, Horii T, Kimura M, et al. (2012) Genome-wide analysis of DNA methylation and expression of microRNAs in breast cancer cells. Int J Mol Sci 13: 8259–8272. pmid:22942701
- 39. Legendre CR, Demeure MJ, Whitsett TG, Gooden GC, Bussey KJ, Jung S, et al. (2016) Pathway Implications of Aberrant Global Methylation in Adrenocortical Cancer. PLoS One 11: e0150629. pmid:26963385
- 40. Wang Y, Zhang J, Xiao X, Liu H, Wang F, Li S, et al. (2016) The identification of age-associated cancer markers by an integrative analysis of dynamic DNA methylation changes. Sci Rep 6: 22722. pmid:26949191
- 41. Ramkaran P, Phulukdaree A, Khan S, Moodley D, Chuturgoon AA (2015) Methylenetetrahydrofolate reductase C677T polymorphism is associated with increased risk of coronary artery disease in young South African Indians. Gene 571: 28–32. pmid:26095803
- 42. Matrisciano F, Panaccione I, Grayson DR, Nicoletti F, Guidotti A (2016) Metabotropic Glutamate 2/3 Receptors and Epigenetic Modifications in Psychotic Disorders: A Review. Curr Neuropharmacol 14: 41–47. pmid:26813121
- 43. Yang J, Zhou JS, Zhao YX, Yang ZH, Zhao HD, Zhang YD, et al. (2015) ABCB1 hypomethylation is associated with decreased antiplatelet effects of clopidogrel in Chinese ischemic stroke patients. Pharmazie 70: 97–102. pmid:25997249
- 44. Spiliopoulos S, Pastromas G (2015) Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications. World J Cardiol 7: 912–921. pmid:26730297
- 45. Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, et al. (2014) Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 35: 209–215. pmid:24067509
- 46. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW (2010) Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 8: 37–42. pmid:19818001
- 47. Tan LA, Keigher KM, Munich SA, Moftakhar R, Lopes DK (2015) Thromboembolic complications with Pipeline Embolization Device placement: impact of procedure time, number of stents and pre-procedure P2Y12 reaction unit (PRU) value. J Neurointerv Surg 7: 217–221. pmid:24553344
- 48. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, et al. (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54: 2430–2435. pmid:16046311
- 49. Schiffrin EL, Lipman ML, Mann JF (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116: 85–97. pmid:17606856
- 50. Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, et al. (2010) Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55: 2427–2434. pmid:20510210
- 51. Hermans MP, Fruchart JC (2011) Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. Ther Adv Chronic Dis 2: 307–323. pmid:23251757
- 52. Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, et al. (2014) Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J 168: 205–212 e201. pmid:25066560
- 53. Su J, Xu H, Yang J, Yu Q, Yang S, Zhang J, et al. (2015) ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis. Lipids Health Dis 14: 122. pmid:26438079
- 54. Fontana P, Berdague P, Castelli C, Nolli S, Barazer I, Fabbro-Peray P, et al. (2010) Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost 8: 2614–2623. pmid:20860677
- 55. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, et al. (2008) The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 6: 54–61. pmid:17949474
- 56. Teng R (2012) Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet 51: 305–318. pmid:22489610